Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer
Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer
This study evaluates the impact of elective regional lymph node irradiation on N1 breast
 cancer patients receiving post-lumpectomy radiotherapy and anthracycline plus taxane
 (AT)-based chemotherapy. We randomly assign patients having one to three metastatic lymph
 nodes (pN1) after breast-conserving surgery (BCS) and AT-based chemotherapy to undergo either
 whole-breast and regional nodal irradiation (WB+RNI group) or whole-breast irradiation alone
 (WBI group).
Objective:

 -  Compare the effect of post-BCS WBI vs. WB+RNI on disease-free survival in pN1 breast
 cancer patients who received AT-based chemotherapy.

 -  Evaluate the impact of WBI or WB+RNI according to molecular subtype of tumor.

 -  Compare the treatment-related toxicities between the WBI and WB+RNI.

 -  Compare the patient's quality of life between the WBI and WB+RNI.

 Outline: This is a a randomized, multi-center, phase III study. Patients are stratified
 according to molecular subtype of tumor (luminal A vs luminal vs luminal HER2 vs
 HER2-enriched vs basal-like), axillary lymph node management (sentinel lymph node biopsy
 [SLN] only vs axillary lymph node dissection+/- SLN) and participating institutions. Patients
 are randomized to one of two treatment arms.

 -  Arm I: Patients receive WB+RNI.

 -  Arm II: Patients receive WBI alone.

 Arm circumference and quality of life (EORTC QLQ-C30 & EORTC QLQ-BR23) are assessed within 2
 weeks prior to randomization, during the last week of radiotherapy, at 3 months after
 completion of radiotherapy, and then annually thereafter for five years.

 Patients are followed at 3 months after completion of radiotherapy and annually thereafter
 for seven years.
Inclusion Criteria:

 -  Histologically proven invasive carcinoma of the breast.

 -  One to three positive axillary lymph nodes (pN1) proven in pathologic specimen.

 -  Prior breast-conserving surgery and post-operative adjuvant chemotherapy including
 taxane.

 -  Administering adjuvant hormonal therapy in cases with hormone receptor-positive tumor.

 -  Administering anti-HER2 therapy in cases with HER2-positive tumor.

 Exclusion Criteria:

 -  Metastases in supraclavicular or internal mammary lymph nodes.

 -  Metastases in distant organs.

 -  Neoadjuvant chemotherapy or hormone therapy before surgery.

 -  Not receiving adjuvant anthracycline and taxane.

 -  Bilateral breast cancer

 -  Previous history of radiotherapy of the ipsilateral breast or supraclavicular lymph
 nodes.

 -  Prior history of other types of cancer, except thyroid cancer, carcinoma in situ of
 the cervix, or skin cancer.